from the promptly evolving field of oncology exploration, correct and effective mutation screening is essential for developing focused therapies. The KRAS companies System plays a pivotal position On this landscape by giving detailed options for KRAS mutation profiling and Assessment. KRAS mutations, found in close to ninety five% of RAS-linked onc